Global efforts to develop and adopt innovative regulatory practices to reduce the environmental impact of medicines have picked up pace after the World Health Organization (WHO) issued a call to action to regulators and pharmaceutical industry stakeholders to adopt innovative processes that prioritize the sector’s sustainability and reduce its environmental impact.
WHO Issues Environmental Sustainability Call To Regulators And Pharmaceutical Industry
The World Health Organization (WHO) has launched an initiative to highlight the pressing global need to reduce the impact of the pharmaceutical industry on the environment while maintaining high standards of safety and efficacy for products.
More from International
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.
• By
A global collaborative inspections pilot reduced the number of individual inspections for participating manufacturing facilities, demonstrating that multiple regulatory authorities can carry out joint inspections using a mix of on-site and remote approaches.
• By
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
• By
The Australian Therapeutic Goods Administration proposed a narrower indication that Eisai rejected.
More from Pink Sheet
• By
The loss of policy analyst, legal, project manager and social scientist positions has experts wondering if the Trump Administration is eyeing a broader effort to limit DTC advertising. The OPDP layoffs are expected to result in delayed reviews of promotional pieces.
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
CMED, which sets medicine prices in Brazil, has published the maximum price adjustment index for 2025.